Published: 2016-12-18

Mycophenolic acid: a drug with a potential beyond renal transplantation

Jammula P. Patro, Pavani Priyadarsini


Mycophenolic acid is an anti-metabolite immunosuppressant. It inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for purine synthesis. It is indicated in prevention of rejection after renal transplantation. It is one of the few drugs, which were discovered more than a century ago and still in active use. This review discusses the other current and potential uses of the drug.


Immunosuppressive agents, Kidney transplantation, Mycophenolic acid, Purines

Full Text:



Sollinger HW. Mycophenolates in transplantation. Clin Transpl. 2004;18:485-92.

Patricia MS, Cees GMK, Coen AS. Use of mycophenolic acid in non-transplant renal diseases. Nephrol. Dial.Transplant. 2007;22(4):1013-9.

Bentley R. Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem. Rev. 2000;100:3801-26.

Kavanagh F. Activities of twenty-two antibacterial substances against nine species of bacteria. J. Bacteriol. 1947;54761-6.

Borroto-Esoda K, Myrick F, Feng J, Jeffrey J, Furman P. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4387-94.

Nicoletti R, De Stefano M, De Stefano S, Trincone A, Marziano F. Antagonism against Rhizoctonia solani and fungitoxic metabolite production by some Penicillium isolates Mycopathologia. 2004;158:465-74.

Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in-vivo. Int. J.Cancer. 1994;57:568-73.

Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis.A review of pharmacology, long-term efficacy, and safety. J Am. Acad. Dermatol. 1987;17:962-71.

Kitchin JES, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses. Journal of the American Academy of Dermatology. 1997;37(3):445-9.

Eugui EM. Fibrogenesis in chronic allograft rejection: underlying mechanisms and pharmacological control. Transplant Proc. 2002;34:2867-71.

Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Annals of the New York Academy of Sciences. 1993;696(1):63-87.

Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14:Suppl 1:s2-8.

MacPhee IA, Spreafico S, Bewick M, Davis C, Eastwood JB, Johnston A, et al. Pharmaco-kinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int. 2000;57:1164-8.

Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Research & Therapy. 2006;8(6):R182.

Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta- analysis. Clinical Journal of the American Society of Nephrology. 2007;2(5):968-75.

Irmgard N, Heinz F, I-Fei F, Adelheid J, Peter B, Josef K. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant. 2008;23:3514-20.

Iaccarino L, Rampudda M, Canova M, Sara DL, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev. 2007;6:190-5.

Chan JFW, Chan KH, Kao RYT, To KKW, Zheng B, Li CPY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606-16.

Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Archives of Dermatology. 2003;139(6):739-42.

Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. The Journal of General Virology. 2006;87(7):1947-52.

Manger B, Hiepe F, Schneider M, Worm M, Wimmer P, Paulus EM, et al. Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study. Clin Exp Gastroenterol. 2015;8:205-13.

Sterneck M, Settmacher U, Ganten T, Sarrazin C, Speidel N, Broering D, et al.Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients. Transplant Proc. 2014;46(1):234-40.

Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant. 2000;14(2):136-8.

Engelen W, Verpooten GA, Van der Planken M, Helbert MF, Bosmans JL, De Broe ME. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol. 2003;60(2):119-24.

El Kabbaj D, Hassani M, Kadiri M, Mounach J, Ouhabi H, Haimeur C, et al. Mycophenolate mofetil associated with progressive multifocal leukoencephalopathy with successful outcome. Saudi J Kidney Dis Transpl. 2012;23(4):790-3.

Matthias S, Christian S, Dominik S, Friederike H, Sabine B, Ralf Christian S, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology. 2010;49(11): 2061-7.